Immune Globulin Articles
A multinational team of investigators exposed cultured neurons with intravenous immunoglobulin (IVIG) to evaluate its effect on downstream signaling pathways involved in neuronal cell death.
Recent studies suggest that the divergent outcomes in Alzheimer’s disease clinical studies of intravenous immune globulin (IVIG) may be due to differences in temporal administration and administered dosages.
An investigational 10% liquid intravenous immunoglobulin product currently under U.S. regulatory review for marketing approval appears to be safe and effective for prophylactic treatment of patients with primary immunodeficiency disorders.
Canadian scientists are working on an intravenous treatment for Alzheimer’s that could halt the progression of the disease and improve cognitive functions.
The U.S.Food and Drug Administration has approved subcutaneous Gammagard Liquid 10% for patients with primary immunodeficiency.
SL Behring has developed a pharmacokinetic model that shows how the body absorbs, distributes, metabolizes and eliminates immunoglobulin following subcutaneous administration.